A look at what the Contemporary Pediatrics® team covered this week.
Dermatological conditions and the relationship to self-image
It is important for pediatric and family nurse practitioners caring for patients with dermatological conditions to be comfortable talking about the conditions with children, adolescents, and their parents.
Lisa Arkin, MD: managing vitiligo in pediatric patients
Dr. Arkin speaks to how the psychological burdens of vitiligo can be exacerbated in younger patients, and what anticipated approvals such as ruxolitinib cream could mean for pediatric populations.
AAP urges school preparedness for medical emergencies
The AAP recently updated their recommendations urging schools to be prepared for emergency medical situations including seizures, diabetes, allergies/anaphylaxis, mental health, substance use, or asthma.
Evaluating new atopic dermatitis medications for children
At the 2022 Maui Derm NP+PA meeting in Colorado Springs, Colorado, a discussion of the newest biologics and how to "mix and match" medications and algorithms.
Breastfeeding reduces the severity of LRTIs in infants
Tralokinumab benefits adolescent eczema patient-reported outcomes at 16 weeks
Pediatric dermatology update: 2022’s top studies
Pharmacies limiting Plan B purchases after Roe v. Wade reversal
FDA approves treatment for chronic weight management in adolescents aged 12 years and older
FDA issues warning for neck floats used for water therapy
Acne in Skin of Color Patients: Preventing PIH
Supreme Court Issues Ruling on Opioid Prescriptions
How to identify common pediatric vulvar conditions
Not just abortion: How the demise of Roe v Wade may impact fertility care
Meena Julapalli, MD, gets ready for the Society for Pediatric Dermatology conference
Between the lines: central precocious puberty
Consider mental health concerns in teens with acne
Solving the physician shortage
Pfizer-BioNTech vaccine efficacy against Omicron in children 5-11 years
At-risk adolescents with depression less likely to endorse suicidal thoughts on questionnaire
May 6th 2024Investigators sought to evaluate characteristics of adolescents with a history of depression who do not endorse risk via the PHQ item 9, which is commonly used to screen for self-harm and suicide risk.
Dupilumab safe, effective for up to 1 year for atopic dermatitis in infants, preschool children
May 3rd 2024According to new study data presented at the 2024 Pediatric Academic Societies Meeting, dupilumab (dupixent; Sanofi and Regeneron) demonstrated positive safety and efficacy results for up to 1 year in infants and preschool-age children with atopic dermatitis.